We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regulators to Ease Big Bank Rules Amid Coronavirus Mayhem?
Read MoreHide Full Article
The coronavirus pandemic has been wreaking havoc on global markets, including the United States. Concerns over the crippling COVID-19 impact on the U.S. economy are keeping investors on their toes.
Banks, including Bank of America (BAC - Free Report) , JPMorgan (JPM - Free Report) , Morgan Stanley (MS - Free Report) , Goldman (GS - Free Report) , PNC Financial (PNC - Free Report) , Wells Fargo (WFC - Free Report) and Citigroup (C - Free Report) , are diving down with the massive sell-off following the Federal Reserve’s announcement of emergency measures and buyback suspensions by major banks. Heightening concerns over the sector’s earnings outlook have jeopardized the market. Curtailment of businesses and consumer activities, in an effort to paralyse the spread of the pandemic, has sparked fears of another recession in the United States and worldwide.
Amid various measures to combat coronavirus’ impact on the economy, Federal regulators are in discussions to ease out liquidity rules on banks, along with increasing the leverage the companies can hold to reduce the financial pressure stalking from the coronavirus pandemic.
Notably, the post-financial crisis framework provided for “counter cyclical capital buffer” or CCyB, which required banks to hold extra buffers above the supplemental capital requirements as per the rules. Nonetheless, though the Fed is not in favor of invoking the CCyB, in the past few years, banks, on average, have paid shareholders above their earnings depleting capital levels.
Moreover, the Office of the Comptroller of the Currency might ease rules for leveraged lending initiated in 2013, though nothing conclusive has been disclosed yet. Also, the proposed rule over supplemental leverage ratio standards and the Current Expected Credit Loss standard implementation date might be relaxed by the OCC.
The CECL accounting standard guides loan-risk measurements and limits risky loans provided by banks. The standard came into effect this year for big banks and has a three-year phase-in period for small banks. However, relaxation of rules might delay implementation for small banks and provide one more year to big banks.
Regulators’ decision might include permit for banks to cater demand of loans with lower credit ratings and provide loans to the companies, including energy and travel, which can be risky in the future. Notably, these companies have been hit hard due to the pandemic and curtailment of global economic activity. Therefore, with easing of capital and liquidity rules, banks might provide further lending support with additional credit risks.
Conclusively, with the coronavirus crisis already hurting the economy, if regulators ease out the rules framed to protect the financial system in such turbulent times, banks will act responsibly to conserve capital with the retention of earnings.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Regulators to Ease Big Bank Rules Amid Coronavirus Mayhem?
The coronavirus pandemic has been wreaking havoc on global markets, including the United States. Concerns over the crippling COVID-19 impact on the U.S. economy are keeping investors on their toes.
Banks, including Bank of America (BAC - Free Report) , JPMorgan (JPM - Free Report) , Morgan Stanley (MS - Free Report) , Goldman (GS - Free Report) , PNC Financial (PNC - Free Report) , Wells Fargo (WFC - Free Report) and Citigroup (C - Free Report) , are diving down with the massive sell-off following the Federal Reserve’s announcement of emergency measures and buyback suspensions by major banks. Heightening concerns over the sector’s earnings outlook have jeopardized the market. Curtailment of businesses and consumer activities, in an effort to paralyse the spread of the pandemic, has sparked fears of another recession in the United States and worldwide.
Amid various measures to combat coronavirus’ impact on the economy, Federal regulators are in discussions to ease out liquidity rules on banks, along with increasing the leverage the companies can hold to reduce the financial pressure stalking from the coronavirus pandemic.
Notably, the post-financial crisis framework provided for “counter cyclical capital buffer” or CCyB, which required banks to hold extra buffers above the supplemental capital requirements as per the rules. Nonetheless, though the Fed is not in favor of invoking the CCyB, in the past few years, banks, on average, have paid shareholders above their earnings depleting capital levels.
Moreover, the Office of the Comptroller of the Currency might ease rules for leveraged lending initiated in 2013, though nothing conclusive has been disclosed yet. Also, the proposed rule over supplemental leverage ratio standards and the Current Expected Credit Loss standard implementation date might be relaxed by the OCC.
The CECL accounting standard guides loan-risk measurements and limits risky loans provided by banks. The standard came into effect this year for big banks and has a three-year phase-in period for small banks. However, relaxation of rules might delay implementation for small banks and provide one more year to big banks.
Regulators’ decision might include permit for banks to cater demand of loans with lower credit ratings and provide loans to the companies, including energy and travel, which can be risky in the future. Notably, these companies have been hit hard due to the pandemic and curtailment of global economic activity. Therefore, with easing of capital and liquidity rules, banks might provide further lending support with additional credit risks.
Conclusively, with the coronavirus crisis already hurting the economy, if regulators ease out the rules framed to protect the financial system in such turbulent times, banks will act responsibly to conserve capital with the retention of earnings.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>